Core Viewpoint - Jilin Aodong announced that its subsidiary Yanji Pharmaceutical has received the "Drug Registration Certificate" for "Sulfate Terbutaline Nebulized Inhalation Solution" from the National Medical Products Administration, which is used to relieve bronchial asthma, chronic bronchitis, emphysema, and other lung diseases associated with bronchospasm [1] Group 1 - The approval of the drug registration certificate enhances the company's product structure [1] - The new product enriches the variety of the company's offerings [1] - This development strengthens the company's core competitiveness [1]

Core Viewpoint - Jilin Aodong (000623.SZ) announced that its subsidiary, Jilin Aodong Pharmaceutical Group Yanji Co., Ltd. (referred to as "Yanji Pharmaceutical"), has received the "Drug Registration Certificate" for "Sulbutamol Sulfate Nebulized Inhalation Solution" from the National Medical Products Administration [1] Group 1 - The indication for Sulbutamol Sulfate Nebulized Inhalation Solution is to relieve bronchial asthma, chronic bronchitis, emphysema, and other pulmonary diseases associated with bronchospasm [1]

Core Viewpoint - Jilin Aodong Pharmaceutical Group's subsidiary has received a drug registration certificate for "Salbutamol Sulfate Nebulization Solution" from the National Medical Products Administration, indicating a significant development in the company's product offerings [1] Company Summary - Jilin Aodong Pharmaceutical Group's subsidiary, Jilin Aodong Pharmaceutical Group Yanji Co., Ltd., has been granted a registration certificate for a new medication [1] - The newly approved medication is indicated for the relief of bronchial asthma, chronic bronchitis, emphysema, and other lung diseases associated with bronchospasm [1]

证券代码:000623 证券简称:吉林敖东 公告编号:2025-049 吉林敖东药业集团股份有限公司 关于控股子公司获得药品注册证书的自愿性信息披露公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，吉林敖东药业集团股份有限公司（以下简称"公司"）控股子公司吉 林敖东药业集团延吉股份有限公司（以下简称"延吉药业"）收到国家药品监督 管理局下发的"硫酸特布他林雾化吸入用溶液"的《药品注册证书》。现就相关 情况公告如下： 一、《药品注册证书》的主要内容 1.硫酸特布他林雾化吸入用溶液 药品通用名称：硫酸特布他林雾化吸入用溶液 英文名/拉丁名：Terbutaline Sulfate Nebuliser Solution 主要成份：硫酸特布他林 剂型：吸入制剂 规格：2ml：5mg 注册分类：化学药品4类 药品注册标准编号：YBH21102025 药品有效期：24个月 包装规格：5支/袋，4袋/盒 处方药/非处方药：处方药 受理号：CYHS2401108 证书编号：2025S02676 上市许可持有人名称：吉林敖东药业集团延吉股份有限公司 上市许可持有人地址： ...

Core Viewpoint - Jilin Aodong has evolved into a holding group company driven by both the pharmaceutical industry and financial capital, aiming to rejuvenate traditional Chinese medicine in modern society through innovation [6][13]. Company Development - Founded in 1957, Jilin Aodong has undergone significant transformations, including the establishment of a pharmaceutical factory in 1981, a shareholding reform in 1993, and its listing on the Shenzhen Stock Exchange in 1996 [6]. - The company has developed a comprehensive industrial chain in the pharmaceutical sector, integrating cultivation, research, production, testing, and sales [7]. Product Innovation - Jilin Aodong's core product, "Anshen Bnuna Liquid," has been a market leader for over 40 years, with a market share of 60% to 70% in its category, generating over 700 million yuan in annual sales [7]. - The company has a diverse product portfolio with 628 drug approval numbers, including 47 exclusive varieties, and has completed the listing of 525 traditional Chinese medicine formula granules [9]. Technological Advancements - The company has invested 1 billion yuan in an automated production line for traditional Chinese medicine extraction, set to be operational by the end of 2024, with an annual extraction capacity of 5,000 tons [10]. - The production process has transitioned to a fully automated system, enhancing efficiency and precision in drug manufacturing [10]. Market Expansion - Jilin Aodong is expanding into the health industry, producing over 200 health products, with some individual products generating over 1 million yuan in annual sales [11]. - The company is also investing in financial sectors, with a reported investment income of 1.206 billion yuan in the first half of 2025, a 53.67% increase year-on-year [12]. Financial Performance - In the first half of 2025, Jilin Aodong achieved a net profit of 1.282 billion yuan, a significant increase of 138.44% compared to the previous year [12]. - The company's total assets reached 34.151 billion yuan, with a debt-to-asset ratio of 11.54%, indicating a strong financial position [12]. Social Responsibility - Jilin Aodong has distributed 4.505 billion yuan in cash dividends over 17 years and has contributed to local economic development through agricultural projects, generating 7.76 billion yuan in output value over the past decade [12].

Core Viewpoint - Jilin Aodong aims to transform traditional Chinese medicine into a modern enterprise through innovation and sustainable development, establishing itself as a leading pharmaceutical company with a dual focus on "pharmaceutical health + financial capital" [2][9]. Group 1: Company History and Development - Jilin Aodong has evolved from a state-owned deer farm established in 1957 to a publicly listed holding company, with significant milestones including the founding of a pharmaceutical factory in 1981 and its listing on the Shenzhen Stock Exchange in 1996 [2]. - The company has developed a comprehensive industrial chain in deer product processing, leveraging over 60 years of experience in breeding deer and achieving GAP certification for its breeding base [3]. Group 2: Product and Market Position - Jilin Aodong's core product, "Anshen Bunan Liquid," has been a market leader for over 40 years, holding a 60% to 70% market share in its category and generating over 700 million yuan in annual sales [3][8]. - The company has a diverse product portfolio with 628 drug approval numbers, including 47 exclusive varieties, and has completed the registration of 525 traditional Chinese medicine formula granules, leading in registration numbers in Jilin Province [5]. Group 3: Innovation and Technology - Jilin Aodong has invested 1 billion yuan in an automated production line for traditional Chinese medicine extraction, set to be operational by the end of 2024, with an annual extraction capacity of 5,000 tons [6]. - The company is embracing digital transformation, moving from experience-based production to data-driven processes, enhancing efficiency and product quality [6]. Group 4: Financial Performance - In the first half of the year, Jilin Aodong reported a net profit of 1.282 billion yuan, a significant increase of 138.44% year-on-year, with total assets reaching 34.151 billion yuan, up 3.48% from the beginning of the year [8]. - The company maintains a low debt ratio of 11.54%, indicating strong financial health within the industry [8]. Group 5: Social Responsibility and Community Engagement - Jilin Aodong has distributed 4.505 billion yuan in cash dividends over 17 years and has created significant economic value for local communities through initiatives in ginseng and deer farming, generating 7.76 billion yuan in output value over the past decade [9]. - The company emphasizes its commitment to reinvesting profits into its pharmaceutical core business to support research, production upgrades, and market expansion [9].

Group 1 - The company has decided to reappoint Beijing Dehao International Accounting Firm as the auditor for the fiscal year 2025, pending approval from the shareholders' meeting [2][12][13] - The audit fee for the current period is set at 1.2 million RMB, which includes 800,000 RMB for financial audit and 400,000 RMB for internal control audit, reflecting an increase of 200,000 RMB from the previous year [10][12] - The audit committee and board of directors have reviewed and approved the reappointment, citing the firm's diligence, independence, and professional competence [11][12][13] Group 2 - The company’s subsidiary, Yanji Pharmaceutical, has received a drug supplement application approval notice for Metronidazole and Fenbufen Capsules, allowing the transfer of the marketing authorization holder from Harbin Huari Biochemical Pharmaceutical Co., Ltd. to Yanji Pharmaceutical [38][39] - The drug is indicated for conditions such as gingivitis and periodontitis, which may enhance the company's product offerings and competitive edge in the market [41]

Group 1 - The company Jilin Aodong announced the appointment of Beijing Dehao International Accounting Firm as the auditor for its 2025 financial report and internal control [2]

Core Viewpoint - Jilin Aodong Pharmaceutical Group Co., Ltd. reported a significant increase in net profit despite a decline in revenue, demonstrating strong operational capabilities and strategic execution [1][4]. Financial Performance - In the first half of 2025, the company achieved operating revenue of 1.126 billion yuan, a year-on-year decrease of 20.21% - The net profit attributable to shareholders reached 1.282 billion yuan, a year-on-year increase of 138.44% [1]. Business Structure - The traditional Chinese medicine segment remains the core business, generating sales revenue of 686 million yuan, accounting for 60.90% of total revenue - The chemical drugs, chain pharmacy wholesale and retail, and health industry segments contributed sales revenues of 143 million yuan, 187 million yuan, and 83 million yuan, representing 12.73%, 16.59%, and 7.39% of total revenue, respectively [1]. Strategic Initiatives - The company is actively reforming its marketing system in the traditional Chinese medicine segment, having completed the marketing restructuring of 22 products and adjusted pricing policies for over 50 products - The company has made significant progress in its Chinese medicine formula granule business, obtaining 525 registration certificates for market access [2]. - A plan to issue convertible bonds to raise 134 million yuan for capital increase in its subsidiary, aimed at constructing a project for Chinese medicine formula granules with an annual production capacity of 2,000 tons [2]. Market Trends - The recovery of the consumer market is expected to accelerate the sales of consumer-oriented traditional Chinese medicine - Long-term growth is supported by an aging population and increasing health awareness among residents, providing a solid foundation for the industry [3]. Operational Efficiency - The company has optimized operational efficiency and adjusted regional layouts by closing some chain pharmacy stores, while enhancing brand management and deepening industry chain collaboration - The chain pharmacy business added 73,000 new members during the reporting period [3]. Asset Management - As of June 30, 2025, the company reported total assets of 34.151 billion yuan, a 3.48% increase from the beginning of the year, and net assets of 29.960 billion yuan, a 3.21% increase - The asset-liability ratio stands at 11.54%, indicating a low level within the industry [4].

Group 1 - The company Jilin Aodong (000623) announced that it will hold its first extraordinary general meeting of shareholders for 2025 on September 19, 2025 [1] - The agenda for the meeting includes the review of the company's 2025 semi-annual profit distribution plan and the proposal regarding the completion of all fundraising projects from the 2018 convertible bonds, as well as the use of surplus funds to permanently supplement working capital [1]